@article {Woyda861，作者= {Woyda，K。和Koebrich，S。和Reiss，I。和Rudloff，S。和Pullamsetti，S。S.和R {\“ U}H. A.和G {\“ U} Nther，A。和Seeger，W。和Grimminger，F。和Morty，R。E.和Schermuly，R。T.}，title = {抑制磷酸二酯酶4增强了新生儿小鼠的肺肺泡化，暴露于Hypyoxia}，音量= {33}，number = {4}，页面= {861--870}，Year = {2009}，doi = {10.1183/09031936.00109008}188bet官网地址）的特征是肺泡化，炎症和异常血管发育受损。磷酸二酯酶（PDE）抑制剂可以影响细胞增殖，拮抗炎症并恢复血管发育和稳态，表明BPD具有治疗潜力。本研究的目的是研究暴露高氧小鼠肺中的PDE表达，并评估PDE4作为BPD治疗靶标的生存能力。将新生儿C57BL/6N小鼠暴露于Normoxia或85 \％氧气中28天。在暴露于高氧的动物中，动物生长和动态呼吸道依从性降低了，与分隔降低，空域增大和间隔壁厚度的增加相似。14天后明显变化，在28天的高氧气暴露后更明显。在mRNA水平上，PDE1A和PDE4A在高氧下下调时上调了PDE1A和PDE4A。免疫印迹证实了蛋白质表达水平上PDE4A和PDE5A中的这些趋势。 Treatment with cilomilast (PDE4 inhibitor, 5 mg{\textperiodcentered}kg-1{\textperiodcentered}day-1) between days 14 and 28 significantly decreased the mean intra-alveolar distance, septal wall thickness and total airspace area and improved dynamic lung compliance. Pharmacological inhibition of phosphodiesterase improved lung alveolarisation in hyperoxia-induced bronchopulmonary dysplasia, and thus may offer a new therapeutic modality in the clinical management of bronchopulmonary dysplasia.}, issn = {0903-1936}, URL = {//www.qdcxjkg.com/content/33/4/861}, eprint = {//www.qdcxjkg.com/content/33/4/861.full.pdf}, journal = {European Respiratory Journal} }